Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 6/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604614 | 1.00 | NPSR1 (0.45) | NPSR1MMEKIF11KCNN4FNTA | |
| SCHEMBL1899106 | 1.00 | NPSR1 (0.45) | NPSR1MMEKIF11KCNN4FNTA | |
| SCHEMBL30278728 | 0.91 | LMNA (0.40) | NPSR1KCNN4KMT2ACYP2C19 | |
| SCHEMBL17981416 | 0.88 | KIF11 (0.48) | NPSR1KIF11KCNN4CYP2C19 | |
| SCHEMBL224241 | 0.86 | MAPT (0.39) | NPSR1KIF11KCNN4KMT2A | |
| SCHEMBL29908038 | 0.86 | NPSR1 (0.43) | NPSR1KIF11KCNN4KMT2A | |
| SCHEMBL28831877 | 0.85 | L3MBTL1 (0.39) | NPSR1MMEKIF11KCNN4KMT2A | |
| SCHEMBL232516 | 0.84 | NPSR1 (0.44) | NPSR1MMEFNTAFNTB | |
| SCHEMBL8682774 | 0.84 | NPSR1 (0.44) | NPSR1MMEFNTAFNTB | |
| SCHEMBL2742288 | 0.84 | KCNN4 (0.46) | NPSR1MMEKIF11KCNN4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-113454058-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound comprising the same, and method for producing the same | 中外制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017035417-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2501674-A2 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | Ranbaxy Laboratories Limited (IN) | 2012-09-26 | — | — | EP | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| WO-2011061610-A2 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
| CN-1230216-A | Breakable signal element apparatus and method | BURSTEIN LAB INC (US) | 1999-09-29 | — | — | CN | disclosed |
| US-5061093-A | NON-IMPACT PRINTING APPARATUS | SEIKO EPSON CORPORATION (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4935299-A | THERMOPLASTIC MAGNETIC INK LAYER CONTAINS TWO OR MORE KINDS OF MAGNETIC PARTICLES DIFFERENT FROM EACH OTHER IN SIZE | SEIKO EPSON CORPORATION (JP) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | NPSR1 1919/4885MME 647/4885KIF11 2086/4885 |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | NPSR1 1047/4885MME 3634/4885KIF11 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.